...
首页> 外文期刊>Cell death & disease. >Mitochondrial dysfunction generates aggregates that resist lysosomal degradation in human breast cancer cells
【24h】

Mitochondrial dysfunction generates aggregates that resist lysosomal degradation in human breast cancer cells

机译:线粒体功能障碍产生抗抵抗人乳腺癌细胞中溶酶体降解的聚集体

获取原文
           

摘要

Disrupting functional protein homeostasis is an established therapeutic strategy for certain tumors. Ongoing studies are evaluating autophagy inhibition for overcoming chemotherapeutic resistance to such therapies by neutralizing lysosomal pH. New and sensitive methods to monitor autophagy in patients are needed to improve trial design and interpretation. We report that mitochondrial-damaged breast cancer cells and rat breast tumors accumulate p53-positive protein aggregates that resist lysosomal degradation. These aggregates were localized to enzymatically-active autolysosomes that were degrading autophagosomes and the autophagic receptor proteins TAX1BP1 and NDP52. NDP52 was identified to associate with aggregated proteins and knocking down NDP52 led to the accumulation of protein aggregates. TAX1BP1 was identified to partly localize with aggregates, and knocking down TAX1BP1 enhanced aggregate formation, suppressed autophagy, impaired NDP52 autophagic degradation and induced cell death. We propose that quantifying aggregates and autophagic receptors are two potential methods to evaluate autophagy and lysosomal degradation, as confirmed using primary human tumor samples. Collectively, this report establishes protein aggregates and autophagy receptors, TAX1BP1 and NDP52, as potential endpoints for monitoring autophagy during drug development and clinical studies.
机译:破坏功能性蛋白质稳态是某些肿瘤的既定治疗策略。正在进行的研究是通过中和溶酶体pH来评估克服化学治疗性对这种疗法的自噬抑制。需要在患者中监测自噬的新和敏感方法,以改善试验设计和解释。我们认为线粒体受损的乳腺癌细胞和大鼠乳腺肿瘤积累了抗溶酶体降解的P53阳性蛋白质聚集体。将这些聚集体本地化为酶促活性的自糖体,其降解自噬体和自噬受体蛋白税1BP1和NDP52。鉴定NDP52与聚集蛋白质相关,并敲下NDP52导致蛋白质聚集体的积累。鉴定税税1BP1以分配聚集体,并击败税1BP1增强的总体形成,抑制自噬,损害了NDP52自噬降解和诱导细胞死亡。我们提出量化聚集体和自噬受体是评估自噬和溶酶体降解的两种潜在方法,如使用原发性人肿瘤样品的确认。本报告集体建立了蛋白质聚集和自噬受体,税收1BP1和NDP52,作为药物开发期间监测自噬的潜在终点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号